COVID-19 and Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers: What Is the Evidence?

This viewpoint reviews the pathophysiological and observational basis for speculating that this group of drugs might worsen clinical outcomes for patients with COVID-19, and summarises specialist guidance to continue these drugs pending more definitive evidence of harm.


Journal of the American Medical Association